Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival

Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1172-8. doi: 10.1164/ajrccm.161.4.9907002.


The clinical records of 487 patients seen at Mayo Clinic Rochester (MCR) during 1994 through 1996 who were diagnosed as having idiopathic pulmonary fibrosis of the usual interstitial pneumonia type (IPF/UIP) were reviewed. Computed tomography (CT) had been done in 94.7% of patients and surgical open lung biopsy (OLB) in 20.3%. Median survival was 3.2 yr. We compared survival as a function of treatment program, based on intent to treat at the time of the initial contact within the study window. Treatment advised included colchicine alone in 167, no therapy in 157, prednisone at maintenance dosages alone in 54, colchicine plus prednisone in 71, and other programs in 38. Oxygen therapy was advised in 133 patients. By univariate analysis, worse survival was associated with prednisone therapy compared with no therapy, and with oxygen therapy compared with no oxygen therapy. However, on multivariate analysis, worse survival was associated with older age, male gender, lower diffusing capacity for carbon monoxide (DL(CO)), lower alveolar volume (VA), and a history of worsening pulmonary function. When adjustment was made for these factors, there was no significant difference in survival between those patients treated with colchicine or prednisone and those on no therapy, and no difference between those on oxygen therapy and those without oxygen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Colchicine / therapeutic use*
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Male
  • Multivariate Analysis
  • Oxygen Inhalation Therapy*
  • Prednisone / therapeutic use*
  • Pulmonary Fibrosis / mortality*
  • Pulmonary Fibrosis / therapy*
  • Retrospective Studies
  • Survival Rate


  • Glucocorticoids
  • Colchicine
  • Prednisone